VITAL KSK HOLDINGS,INC. FY2027 Q1 Earnings Report

Quick View

Executive Summary

Although the Company secured revenue growth, both Operating Income and Net Income fell below the previous year due to increases in selling, general and administrative expenses and the tax burden, resulting in higher revenue but lower earnings. Revenue was ¥15.460B (+4.3% year on year), Operating Income was ¥0.064B (-20.2%), Ordinary Income was ¥0.084B (-16.2%), and Net Income attributable to owners of the parent was ¥0.036B (-48.2%). The gross profit margin improved by +0.1pt to 8.0%, but the SG&A ratio deteriorated by +0.2pt to 7.6%, resulting in lower Operating Income. In addition, the effective tax rate was high at 58.8%, which widened the decline in Net Income.

Factors Driving Earnings Fluctuations

【Revenue】Revenue increased 4.3% year on year to ¥15.460B. The core Pharmaceutical Wholesale Business led overall performance, with revenue of ¥14.780B (+4.3%), maintaining its growth trend as the central business, accounting for 93.8% of sales to external customers. The Nursing Care Rental and Other Business posted strong growth of 19.5% to ¥0.237B, while the Veterinary Pharmaceutical Wholesale Business was largely flat at ¥0.308B (-0.3%).

【Profit and Loss】Operating Income declined 20.2% year on year to ¥0.064B, as the ¥0.082B increase in SG&A expenses exceeded the ¥0.066B increase in gross profit. The Operating Income margin declined to 0.4% from 0.5% in the previous year, as the +0.1pt improvement in the gross profit margin was offset by the +0.2pt increase in the SG&A ratio. Ordinary Income was ¥0.084B (-16.2%); although non-operating income of ¥0.027B, including ¥0.012B in dividend income, provided support, it was insufficient to offset the decline in Operating Income. Extraordinary income of ¥0.008B, comprising a ¥0.004B gain on the sale of investment securities and a ¥0.004B gain on the sale of fixed assets, was recorded as a temporary factor, but declined from ¥0.030B in the previous year, limiting its contribution to Net Income. Against Profit Before Tax of ¥0.093B, income taxes and other taxes of ¥0.054B were recorded, resulting in a high effective tax rate of 58.8%. Consequently, Net Income attributable to owners of the parent declined 48.2% year on year to ¥0.036B, a sharper decline than Ordinary Income. Despite revenue growth, higher expenses and an increased tax burden pressured earnings, resulting in higher revenue but lower earnings.

Segment Analysis

The core Pharmaceutical Wholesale Business remained solid in both scale and profitability, with revenue of ¥14.780B (+4.3%), Operating Income of ¥0.110B (+1.9%), and a profit margin of 0.7%, supporting the majority of Company-wide Operating Income. In contrast, the Pharmacy Business recorded revenue of ¥0.490B (+1.1%), but its operating result fell to a loss of ¥0.006B from a profit in the previous year, resulting in a profit margin of -1.2%. The Veterinary Pharmaceutical Wholesale Business generated revenue of ¥0.308B (-0.3%) and Operating Income of ¥0.007B (-5.2%), but its profit margin of 2.4% was the highest among all segments. The Pharmaceutical Business recorded an operating loss of ¥0.042B, which expanded further from the previous year's loss (-37.3%), while the Nursing Care Rental and Other Business increased revenue 19.5% to ¥0.237B but remained at an operating loss of ¥0.006B. In addition to the low-margin structure of the core business, losses in the three non-core segments are diluting the Company-wide profit margin.

Key Financial Indicators

【Profitability】The Operating Income margin was 0.4%, slightly below 0.5% in the previous year. Although the gross profit margin improved to 8.0% from 7.9%, the SG&A ratio increased to 7.6% from 7.4%, offsetting the improvement. The Net Income margin, based on income attributable to owners of the parent, was 0.2%, down from 0.5% in the previous year.【Cash Quality】Cash and deposits totaled ¥2.276B, while interest-bearing debt, comprising the total of short-term borrowings, current portion of long-term borrowings, and long-term borrowings, was approximately ¥0.460B, securing net cash of approximately ¥1.817B. Accounts receivable increased 5.1% year on year, while inventories decreased 6.1%, indicating a change in the composition of working capital.【Investment Efficiency】ROE was 0.3% based on quarterly results, and the Equity Ratio was 35.5%, down from 36.6% in the previous year. Total assets were ¥32.228B, remaining almost flat year on year, while net assets were ¥11.592B, down from ¥11.871B in the previous year.【Financial Soundness】Current assets of ¥19.757B compared with current liabilities of ¥18.832B resulted in a current ratio of 104.9%. Non-current liabilities were ¥1.805B, relatively small compared with current liabilities, and the liability structure was centered on short-term trade payables, including accounts payable of ¥17.406B.

Cash Flow Analysis

As the Company does not disclose a cash flow statement, cash trends are assessed based on changes in the balance sheet. Cash and deposits were ¥2.276B, remaining almost flat from ¥2.295B in the previous year. In terms of working capital, accounts receivable and notes receivable increased 5.1% year on year, while inventories decreased 6.1% and accounts payable and notes payable increased 2.5%. Interest-bearing debt, comprising short- and long-term debt, was approximately ¥0.460B, a slight decrease from approximately ¥0.483B in the previous year. After deducting this from cash and deposits, the Company maintained net cash of approximately ¥1.817B. As the increase in accounts receivable exceeded the reduction in inventories, funds appear to have become somewhat tied up in working capital, particularly trade receivables, and the timing of cash conversion may be affecting capital efficiency.

Quality of Earnings

Recurring earnings are centered on the core commercial trading business. Non-operating income of ¥0.027B comprised stable items such as dividend income of ¥0.012B and interest income of ¥0.001B, and was limited in scale at approximately 0.2% of revenue. As a temporary factor, the Company recorded extraordinary income of ¥0.008B, consisting of a ¥0.004B gain on the sale of investment securities and a ¥0.004B gain on the sale of fixed assets. However, this declined from ¥0.030B in the previous year, and its contribution to earnings was limited. Against Ordinary Income of ¥0.084B, Net Income attributable to owners of the parent was ¥0.036B. This gap was attributable to income taxes and other taxes of ¥0.054B against Profit Before Tax of ¥0.093B and the high effective tax rate of 58.8%. The significant divergence between earnings at the Ordinary Income stage and final Net Income is an important consideration when evaluating earnings quality. The change in asset composition, namely the increase in accounts receivable and decrease in inventories, also provides a basis for assessing the pace of cash conversion from an accrual perspective.

Earnings Forecasts and Guidance

Progress against the Full-Year plan was approximately in line with normal levels for Revenue at 24.9% (¥15.460B/¥62.000B). However, progress was slower for Operating Income at 15.7% (¥0.064B/¥0.410B), Ordinary Income at 16.9% (¥0.084B/¥0.500B), and Net Income attributable to owners of the parent at 4.8% (¥0.036B/¥0.750B). No revisions were made to either the earnings forecast or the dividend forecast, both of which were stated as “None.” The Company is maintaining its plan based on cost control and improvements in loss-making segments in the second half, as well as normalization of the tax burden. The Full-Year Ordinary Income forecast calls for a substantial 36.1% year-on-year decline, representing a conservative outlook consistent with progress during the first half.

Shareholder Returns

The annual dividend forecast is ¥70.00, with no revision made during the current quarter. Based on the number of shares outstanding of 51,903 thousand shares less treasury shares of 3,864 thousand shares, total annual dividends are estimated at approximately ¥0.336B, implying a Payout Ratio of approximately 45% against the Full-Year Net Income forecast of ¥0.750B attributable to owners of the parent. Treasury shares increased to ¥0.448B from ¥0.396B in the previous year, confirming progress in share repurchases. The Payout Ratio based solely on dividends is approximately 45%. Considering the cash and deposits balance of ¥2.276B and the net cash position of approximately ¥1.817B, the Company appears to have a certain degree of flexibility in funding dividends.

Risk Factors

1. Concentration risk in the business portfolio: The Pharmaceutical Wholesale Business accounts for 93.8% of sales to external customers (¥14.780B/¥15.460B), creating a structure in which supply-demand and pricing trends in this business have a significant impact on Company-wide performance.

2. Low-margin structure and continued losses in non-core businesses: The Company-wide Operating Income margin is low at 0.4%, while the Pharmacy Business (operating loss of ¥0.006B), Pharmaceutical Business (loss of ¥0.042B), and Nursing Care Rental and Other Business (loss of ¥0.006B) all reported losses, diluting profits from the core business.

3. Risks related to the tax burden and working capital: The effective tax rate for Q1 was high at 58.8%, amplifying fluctuations in Net Income. In addition, accounts receivable increased 5.1% year on year while inventories decreased 6.1%, and changes in the asset composition may affect the timing of cash conversion.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (trading)

Profitability and Returns

Both the Company's Operating Income margin and Net Income margin are significantly below the industry median, placing the Company in the low-profitability group within the industry.

Growth and Capital Efficiency

The Revenue growth rate exceeds the industry median, indicating that the pace of revenue growth is relatively high within the industry.

Source: Compiled by the Company

Key Takeaways from the Earnings Results

1. Despite revenue growth, the increase in the SG&A ratio (+0.2pt) reduced the Operating Income margin to 0.4%. The increase in expenses offset the improvement in the gross profit margin (+0.1pt), determining the Company's profitability during the current period.

2. The high effective tax rate of 58.8% widened the decline in Net Income attributable to owners of the parent (-48.2%) compared with Ordinary Income (-16.2%). Progress toward the Full-Year plan was also slower at the Net Income level, with progress of only 4.8%, than at the Revenue and Ordinary Income levels.

3. While the core Pharmaceutical Wholesale Business maintained higher revenue and higher earnings, the Pharmacy, Pharmaceutical, and Nursing Care Rental and Other businesses each recorded operating losses. Improving the profitability of the non-core businesses will be a key issue in restoring the Company-wide profit margin.

Theoretical Share Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly disclosed data using a residual income model (Ohlson-type model with an explicit five-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥1,916–¥2,025 at ±1% for the cost of equity, and ¥1,955–¥1,978 at ±0.1 for ω.

Notes:

• Normalized EPS calculated from Ordinary Income and other figures is used to exclude the impact of temporary profit and loss items (the Company's forecast EPS is ¥155.0).
• As forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used; there is a timing gap with the Full-Year forecast.
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual income model / Interest rate reference month: 2026-07 / This value does not forecast or guarantee future share prices)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.

---End of Report---